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ABSTRACT 
 
Introduction:  
Clostridium difficile infection (CDI) affects the digestive system; the symptoms range 
from mild to severe. In healthy individuals CDI is asymptomatic; however certain 
antibiotics and other medication can disturb the normal gut flora predisposing to CDI.  
This may lead to unnecessary hospitalisation or a prolonged hospital stay, which can 
be more debilitating in immunocompromised patients. Thus, judicious antibiotic use 
is crucial; however certain conditions require treatment that may alter normal flora, 
which is a predisposing factor for CDI. 
 
Objective: To ascertain the prevalence of Clostridium difficile infection in a cohort of 
HIV positive patients with diarrhoea at Chris Hani Baragwanath Academic Hospital. 
(CHBAH) over a 12 month period. 
 
Design: This was a prospective study. 
 
Methods: 
 Prospective study, at CHBAH 
 200 HIV positive patients with diarrhoea were evaluated. 
 Clinical records of the selected patients were accessed. 
 A questionnaire was used to identify risk factors for Clostridium difficile 
infection (CDI) in the selected patients.  
 Stool analysis was used to diagnose CDI.  
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Results: 
Fifty-three patients (26.5%) had CDI.  
The most significant factors associated with an increased risk for CDI were: 
 Anti-tuberculous treatment; most likely Rifampicin 
 Antibiotic use, especially penicillin based drugs; clindamycin and 
carbapenems. 
 
 
A very low CD4 count was not a strong predictor for CDI (p=0.62) after adjusting for 
confounders (Viral load, concurrent co-morbid disease, use of antibiotics and anti-
tuberculosis drugs). 
 
 
Conclusions: 
In our cohort of 200 patients, fifty-three (26.5%) had CDI. The risk factors identified 
were use of anti- TB drugs, common antibiotics associated with C.difficile.   
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1.0 CHAPTER 1 
1.1 Introduction and literature review 
1.1.1 Clostridium difficile 
Clostridium difficile (C.difficile) is a Gram-positive rod shaped bacterium of the genus 
Clostridium, it exists in vegetative or spore forms. The antibiotics can eradicate the 
normal gut flora leading to CDI presenting with diarrhoea and gastrointestinal 
complications. (1). Scientific classification of C. difficile is shown in table 1.1 below 
 
Table 1.1: Scientific classification of C. difficile 
Kingdom  Bacteria  
Phylum  Firmicutes 
Class  Clostridia  
Order  Clostriadiales 
Family  Clostridiaceae 
Genus  Clostridium  
Species  C. difficile  
 
(2) 
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Figure 1.1: Clostridium difficile 
(3) 
 
Clostridia bacteria are anaerobic gram positive rods which forms spores. Its first 
description was in 1935, and at that stage, it was not thought of as a pathogen but as 
the normal faecal flora of healthy newborns. It is known to cause antibiotic–
associated diarrhoea (AAD) because the antibiotics destroy the normal gut 
microbiota leading pseudomembranous colitis (PMC). This was elucidated around 
1970(1, 4) 
C.difficile secretes two types of exotoxin strains which are toxin A (TcdA an 
enterotoxin) and toxin B (TcdB a cytotoxic).Production of the above mentioned 
strains results in the disease and the prognosis depends on immunity of the host and 
toxin strain virulence produced.  The clinical manifestations of CDI can vary from 
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asymptomatic presentation to severe diarrhea, PMC, toxic megacolon, and colonic 
perforation (1, 4, 5). 
 
Dating back about ten years ago, there is a significant rise in the occurrence of CDI 
and the complications of Clostridium difficile-associated diarrhea (CDAD). This is 
partly attributable to the appearance of the new strain, known as North American 
pulsed field type 1 (NAP1).(6).There is a difference between Clostridium difficile 
colonisation and Clostridium difficile infection the former exhibits no symptoms even 
though patients have a positive test for organism and/or toxins.  Colonisation is more 
common than infection. Patients with infection will exhibit symptoms secondary to 
the organism and/toxins (7, 8). 
 
1.2 Epidemiology of Clostridium difficile infection  
Previous research done at America, more than 44,000 HIV positive patients were 
recruited  from 1992-2002, the most common aetiology of the diarrhoea was found to 
be  C.difficile   (9). 
About fourteen years ago they discovered an epidemic strain leading to the rise of 
the occurrence of CDI and its complications. (10). 
Diarrhoea is one of the most common presentations in HIV positive patients with 
more than 50% of these patients presenting with diarrhoea during course of their 
illness. Approximately 75 % of HIV positive patients will experience morbidity and 
mortality related to diarrhoea. In 50% of cases, HIV positive patients presenting with 
diarrhoea have no identifiable aetiology. It is then suggested that the symptoms are 
attributed HIV enteropathy (12)  
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1.3 Pathogenesis 
C.difficile produces toxins and spores that are unaffected by heat and can survive in 
the environment for long. It is a normal commensal of the gut. The gut microbiota 
prevents overpopulation of C.difficile (1, 4-6, 11, 12). Antibiotics administration can 
change the normal gut microbiota predisposing patients to antibiotic associated 
diarrhea (AAD) .C.difficile is the most significant cause of AAD which can complicate 
to PMC. This is because C.difficile produces exotoxin that destroys mucosa by 
causing colon inflammation. An impaired barrier in the epithelial function has been 
described, it is postulated that diarrhoea by leak flux mechanism is secondary to 
destruction of the tight junctions as a result of HIV chronic inflammation states that 
produce cytokine. Denervation of anatomy, dysregulation of immune system, 
malabsorption of bile acid and local production of lymphokines are other mechanism 
proposed.(1,4-7)    
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Patients will not get CDI if their normal gut flora is not disrupted by antibiotics (1). 
Once antibiotic treatment is initiated, CDI with strain resistance to antibiotics is more 
likely while the antibiotic is being administered because of presence of antibiotic in 
the gut (2). When the antibiotic treatment is withdrawn, the antibiotic levels in the gut 
drops significantly and rapidly, however the gut flora remains disturbed for some time 
as indicated by the break in the graph, this depends on the type of antibiotic given 
(3). During this time, patients can be infected with C.difficile .When   the microflora 
recovers, colonization resistance to C. difficile is restored (4). 
 
Figure 1.2: C-difficile and antibiotic pathogenesis 
(13)  
 
When common antibiotics associated with CDI have been administered, the gut flora 
will be disrupted exposing gut to be overrun by C.difficile organism leading to CDI.  
This overpopulation results in symptoms of CDI. The feared complication C.difficile is 
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pseudomembranous colitis, which has high mortality especially if it progress to  toxic 
megacolon (10). 
Several toxins are produced by C.difficile strains. Tcd A and B can both cause 
diarrhoea and inflammatory response, however their relative contributions have been 
debated (1, 14). 
It is described in literature that the Rho family of GTPases can be inactivated by 
toxins A and B are glucosyltransferases. Actin depolymerisation is induced by exo- 
toxins following a decrease in the ADP-ribosylation of the low molecular mass 
glutamyltranspeptidase (GTP)-binding Rho proteins. The toxins that are bound to 
receptors can enter intracellularly and catalyse specific alterations of Rho proteins, 
small (GTP)-binding proteins that helps in structure of cytoskeleton, polymerisation 
of actin, and movements of the cell. Binary toxin has been previously researched but 
its mechanism is still under development (14). 
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Figure 1.3: Pathogenesis of C.difficile. 
(15)  
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1.4 Risk Factors 
 Antibiotic exposure: 
o Penicillin based drugs (amoxicillin, ampicillin, augmentin) 
o Clindamycin 
o Carbapenems  
o Cephalosporin (especially second and third generation) 
o Less commonly implicated: protein synthesis inhibitors (erythromycin, 
azithromycin, clarithromycin) (16, 17) 
 Proton pump inhibitors 
 Antineoplastic agents 
 Hospitalisation:  
o Prolonged stay 
o Intensive Care Unit 
o Sharing room with infected person if strict infection control measures 
neglected 
 Advanced age 
 Malignancies 
 Necrotising colitis 
 Inflammatory bowel disease 
 Renal failure 
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1.5 Transmission 
C. difficile is found in the stool. Virtually anything that can be contaminated with 
infected stool can serve as a main entry for C. difficile spores that are then 
transferred to patients, mainly via the contaminated. (1)  
1.6 Clinical features  
Patients with C. difficile infection may present with the following symptoms and 
signs. (1) 
Mild to moderate or severe diarrhoea  
Cramping abdominal pain 
Anorexia 
Malaise 
Fever  
These symptoms may mimic inflammatory bowel disease associated colitis 
The clinical features of C. difficile infection vary from asymptomatic to diarrhoea with 
severe colitis 
Table 1.2: Clinical manifestations of Clostridium difficile infection 
Type of 
infection  
Diarrhea  Other symptoms  Physical 
examinatio
n  
Sigmoidoscopi
c examination  
Diarrhea with 
colitis 
≥loose stool  
faecal white 
cell count  
 
Occult 
bleeding 
  
Hematochezi
a 
(uncommon) 
Nausea, loss of 
appetite, fever, 
fatigue, 
dehydration, 
leukocytosis with 
left shift 
 Tenderness 
and 
distention of 
abdomen 
 Non -specific 
colitis 
Severe colitis 
Diarrhea 
varies from 
severe  to 
diminished 
Pyrexia,tachycardi
a, lerthagic and 
abdominal pain 
peritonitis 
Only proctoscpy 
recommended 
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because of 
paralytic ileus 
and 
megacolon  
 
Asymptomati
c carriage 
Nil  Nil  Normal Normal 
(18) 
1.7 Management 
1.7.1  The following stool investigations are recommended 
Detailed laboratory inspection of stool sample is the accepted diagnostic test for CDI. 
(1, 8). An assortment of laboratory tests has evolved. The specific test used may 
differ from institution to institution. The different tests that may be used are described 
below.  
Stool microscopy, culture and sensitivity (mcs): This is the most sensitive test 
available; this is however less specific due to the presence of non-toxigenic 
Clostridium difficile strains.  (8) 
 
Molecular test: The PCR assay test has the high sensitivity and specificity for 
detecting toxin B produced by C-difficile. (1) 
Antigen detection: This is a rapid test that detects antigens by latex agglutination or 
immunochromatographic assays. This test does not distinguish the type of toxin 
produced. (8) 
Tissue cytotoxicity: This assay detects both strains (toxin A and toxin B); it has a 
turnaround of approximately two days and is accepted as an accurate laboratory 
measure (gold standard) for diagnosis of C.difficile. (8)  
Enzyme immunoassay: This assay identifies the presence of both toxin A and toxin 
B or either. However because of negative toxin A, and toxin B strain causing 
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disease, many institutions prefer testing for toxin B. This test is rapid and results may 
be available within two hours. (8)  
 
At CHBAH, they use real time PCR for toxigenic C.difficile (GeneXpert). This assay 
specifically targets toxin B and binary toxin genes as well as the tcdC gene deletion 
for differentiating between toxigenic C.difficile and NAP1/027/B1 variant.  
 
1.7.2 Prevention 
 Appropriate antibiotic use: use antibiotics only when indicated 
 Proper hand washing: all health care providers should be encouraged to wash 
hands with soap (not alcohol scrub) between patients 
 Barrier methods: patients with CDI must be isolated and contact precautions 
employed and visitors should be encouraged to wash hand before and after 
contact with patients 
 Proper cleaning of all material using soap known to kill the spores 
 Community educational program to teach community about CDI and 
measures to control it 
 Inform infection control team 
 
1.7.3 Pharmacological 
New therapies have evolved for CDI but traditional antibiotics are specifically 
effective against C. difficile.(19, 20,21). 
 Metronidazole five hundred milligram(mg) three times per day for ten days is  
approved and used as first line , because it is effective and cheap 
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 Failure to clinical response to the above within 5-7 days prompt consideration 
to oral vancomycin (125mg orally, thrice a week) as second line, and may be 
used as first line in the following cases:  
o The organism is resistant to metronidazole 
o Allergy to metronidazole 
o Pregnant and breastfeeding  patients  
o In patients where colon may not be reached (diversion of colon, 
ileostomy and proctosigmoidectomy).In this case it should be given via 
enema.Intravenous administration of vancomycin is not recommended 
because of the limited therapeutic concentration of the gut lumen, it 
must be administered orally or by enema  
 Dual metronidazole with vancomycin is recommended in severe and 
complicated  CDI 
 Rifaximin 
 Surgical consult is mandatory in complicated CDI 
 Faecal microbiota transplantation is also an option in stable patient with 
recurrent CDI. 
 
1.8 Problem statement and rationale  
The prevalence of C.difficile and risk factors associated with it has not been defined 
in HIV positive patients at CHBAH. 
The rationale for this study is to define prevalence and risk factors associated with 
CDI in HIV positive patients.  
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1.9 Objectives  
1.9.1 Primary objective 
 Primarily to ascertain the prevalence of CDI in a cohort of HIV positive 
patients at CHBAH. 
 
1.9.2 Secondary objective 
 To evaluate the risk factors associated with acquiring CDI in HIV positive 
patients. 
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2.0 CHAPTER 2 
2.1 MATERIAL AND METHODS 
2.1.1 Study Design and source of data 
This was a single center prospective and cross sectional study using data of HIV 
positive patients who presents to a general medical ward with diarrhoea. The study 
period was 12 months to enable the researcher to recruit the sample size stated. 
Patient’s demographics, drug history, co-morbid disease, HIV status, HIV-viral load 
(VL), CD4 count, stool analysis (mcs and PCR), Full blood count (FBC), Liver 
function test (LFT), Urea and electrolyte (U and E) and other variables were obtained 
as shown in appendix A. The study was approved by the University of the 
Witwatersrand Human Research Ethics Committee (Medical) (Protocol number 
131032). 
 
2.1.2 Inclusion criteria 
 
Age >18 years 
HIV positive in-patients with diarrhoea (≥ 3 stool in 24 hours) 
Written consent 
 
2.1.3 Exclusion criteria 
Age <18 years 
Non –hospitalised patients 
HIV status unknown or negative 
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2.2 Sample size 
HIV positive patients with diarrhoea, admitted to the medical wards at CHBAH were 
evaluated.  
Two hundred and thirty-five patients were assessed. A sample size of 200 was 
established to aid completion of the study within the specified period. 
 
2.3 Data 
The data source was clinical records of internal medicine patients at CHBAH and a 
questionnaire was used.  
 
2.4 Variables 
 CD4 counts 
 Viral load 
 Co-morbidities 
 Anti-TB drugs 
 Antibiotics 
 Use of both anti-TB drugs and antibiotics concurrently  
 Proton pump inhibitors 
 Laboratory variables  - FBC, U & E and LFT  
 
2.5 Data management and analysis 
Data were entered into a Microsoft Excel Spread shift and transferred to STATA 14 
(Statacorp) for statistical analysis. Strict confidentiality of patient’s records was 
observed. Names of patients were not used. Means and percentages were 
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computed for continuous and categorical variables respectively, and compared by 
CDI. Mann-Whitney test was used to compare continuous variables while Chi-square 
or Fischer’s exact tests were used to compare categorical variables.The logistic 
regression analysis using unadjusted and adjusted odds ratio OR 95%CI) was used. 
The level of significance was set at p value of 0.05.  
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2.6 Outcomes measures and Definition 
2.6.1 Primary outcome 
Positive CDI is defined as positive PCR for toxigenic C.difficile on stool analysis. 
2.6.2 Secondary outcome 
Risk factors associated with C.difficile were measured using regression analysis 
(unadjusted odds ratio confidence interval and adjusted odds ratio confidence 
interval). 
 
2.7 Ethical consideration  
Ethical clearance to conduct the study was obtained from the Human Research 
Ethics Committee (Medical) of University of the Witwatersrand. Permission was also 
sought from the chief executive officer of CHBH. Confidentiality was respected as no 
patient identifiers were used in data collection, analysis and reporting. 
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3.0 CHAPTER 3 
 
3.1 RESULTS 
3.1 Baseline characteristics 
A total of two hundred patients from CHBAH internal medicine ward were recruited in 
the study over a 12-month period. The baseline characteristics are shown in table 
3.1. The mean age was 41.18 years ± 10.9 (SD), 106 (53%) were male and 94 
(47%) were females. 
Of the studied cohort 91 (45.5%) had very low CD4 counts (<200 cells/µL), 60 
(30.0%) had low CD4 count (201-499cells/µL), 36 (18%) had normal CD4 count 
(500-2010 cells/µL) and the remaining 13 (6, 5%) CD4 counts were unknown. The 
viral load was detectable in 78 (39.0%) and only 12 (6%) had a lower than detectable 
viral load. In 110 (55%) of these patients the viral load was not measured. 
The results showed that 163 (81.5%) 158 (79.0%) and 65 (34.8%) patients had an 
abnormal full blood count (FBC), urea and electrolyte (U&E) and liver function test 
(LFT) respectively. 
 
Of the studied cohort, 156 (78%) had concurrent co-morbidities, of which TB was 
noted in 74 (37.0%) patients and 82 (41.0%) had other co-morbidities. Only 44 (22%) 
patients had no co-morbidities.  
 
On drug related factors, 87(43.5%) patients were on antibiotics, 107 (53.5) were not 
on antibiotics and for 6(3%), it was not known if they were on antibiotics or not. Out 
of the 87 patients who were on antibiotics, 60 (69.9 %) were on common antibiotics 
associated with CDI and only 3 (3.5%) were on antibiotics not commonly associated 
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with CDI. About 24 (27.5%) patients were on antibiotics but they did not know which 
type of antibiotic they used. 
Patients who were on anti-TB treatment numbered 74 (37.0%) and only 8 (4%) used 
Proton pump inhibitors.  
Of the entire study population, 53 (26.5 %) were C.difficile positive. 
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Table 3.1: Baseline characteristics of the study patients  
 N=200 
Demographic characteristics N (%) 
Sex   
Male 106 (53.0) 
Female 94 (47.0) 
Age (mean±sd) 41.18±10.9 
HIV related factors  
CD4 count (cells/µL)  
Very low (<200) 91 (45.5) 
Low (201-499) 60 (30.0) 
Normal (500-2010) 36 (18.0) 
Unknown 13 (6.5) 
Viral load (copies/ml)  
LDL 12 (6.0) 
Detectable 78 (39.0) 
Unknown 110 (55.0) 
Concurrent co-morbidites  
TB (yes) 74 (37.0) 
Other (yes) 82 (41.0) 
None 44 (22.0) 
Laboratory characteristics  
Stool analysis (yes) 200(100%) 
Abnormal FBC 163 (81.5) 
Abnormal U&E 158 (79.0) 
Abnormal LFT 65 (34.8) 
Drug related factors  
Use of antibiotics  
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Yes  87 (43.5) 
No 107 (53.5) 
Unknown 6 (3.0) 
Use of common antibiotic associated with 
C.difficile (Out of 87)  
Yes 60 (69.0) 
No 3 (3.5) 
Don’t know 24 (27.5) 
Use of Anti-TB drugs (yes) 74 (37.0) 
Use of PPI (yes) 8 (4.0) 
CDI (yes) 53 (26.5) 
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3.2 Factors associated with C-difficile infection 
There were 53(26.5%) patients with CDI. There was no statistical difference in the 
proportion between males and females. Gender was statistically insignificant 
(p=0.73), 27 (50.9%) were males and 26 (49.1%) were females, as shown in table 
3.2.The value of CD4 count (cells /µL) was statistically significant (p<0.001). From 
this group of patients with CDI, 41 (77.4 %) had a very low CD4 count (<200 
cells/µL), 9 (17.0%) had a low CD4 count (201-499 cells/ µL) only 1 (1.8%) had a 
normal CD4 count (500-2010 cells/µL) and 2 (3.8%) had unknown CD4 counts. Viral 
load level were also statistically significant (p<0.001). None from the patients whose 
viral load were checked had a lower than detectable viral load, 38 (71, 7%) had a 
detectable viral load and 15 (28.3%) of these patient’s viral load was not known. 
 
The presence of  co-morbidities was statistically significant (p<0.001).Tuberculosis 
was noted in 36 (67.9%) and 17 (32.1%) had other co-morbidities. Antibiotic use was 
statistically significant (p<0.001) and the majority of these patients 41(77.4%) used 
antibiotics, only 10 (18.8%) did not use antibiotics. A small number, 2 (3.8%) did not 
know if they used antibiotics, none used uncommon antibiotics (antibiotic not 
commonly associated with CDI). Common antibiotic use was noted in 32 (60.4%)   
and only 9 (17%) did not know which antibiotic they used. There were 12(22.6%) 
patients who were only on anti-TB treatment and not antibiotics. Anti-TB drugs use 
was statistically significant (p<0.001), with 36 (67.9 %) patients that used anti-TB 
therapy and 17 (32.1%) did not use anti-TB therapy because they did not have TB 
and 27 (50.9%) used both antibiotics and anti-TB drugs. 
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Table 3.2: Factors associated with c-difficile positive 
Variables c-diff positive 
(n=53) 
p-value 
Sex   0.73 
Male 27 (50.9)  
Female 26 (49.1)  
CD4 count (cells/µL)  <0.001 
Very low (<200) 41 (77.4)  
Low (201-499) 9 (17.0)  
Normal (500-2010) 1 (1.8)  
Unknown 2 (3.8)  
Viral load (copies/ml)  <0.001 
LDL 0 (0.0)  
Detectable 38 (71.7)  
Unknown 15 (28.3)  
Concurrent morbid conditions  <0.001 
TB (yes) 36 (67.9)  
Other (yes)* 17 (32.1)  
Use of antibiotics  <0.001 
Yes  41 (77.4)  
No 10 (18.8)  
Unknown 2 (3.8)  
Antibiotic type  <0.001 
Uncommon 0 (0.0)  
Common 32 (60.4)   
Unknown 9 (17.0)  
Not on antibiotic but on TB treatment 
only 
12 (22.6)  
Use of Anti-TB drugs   <0.001 
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Yes 36 (67.9)  
No 17 (32.1)  
Both antibiotic use and anti-TB drug 
use 
27 (50.9) <0.001 
 
Legend 
 Comorbidities identified: Meningitis, pneumonia, hematological and non-
hematological malignancies 
3.3 Comparison of CDI Negative with CDI POSITIVE 
 
Mean age for CDI positive was higher than CDI negative (z=2.226,p=0.03), this was 
a continuous variable, however this had a nominal distribution. 
Gender did not reveal any difference in the distribution percentage of CDI positive 
and CDI negative. 
The percentage of CDI positive with very low CD4 count was higher than the 
percentage of CDI negative with very low CD4 count. (p<0.001) 
The same observation was also consistent with detectable viral load in CDI positive 
and CDI negative. (p=0.001). 
 Patients with CDI and had TB had a higher percentage distribution than the patients 
of the same group who were CDI negative. (p<0.001) 
Antibiotic use revealed a higher percentage of distribution in CDI positive than CDI 
negative. (p<0.001)  
The use of anti-TB drugs also revealed a higher percentage of distribution compared 
to patients who were CDI negative on anti-TB therapy. (p<0.001) 
 
Table 3.3: Comparison of patients who are CDI-positive with CDI-negative 
patients  
 
Variable 
Patients  
CDI-positive 
(N=53) 
CDI-
negative(N=147)  
 
p-
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n (%) n (%) value 
Demographic 
characteristics 
   
Age (mean±sd) 38.28±9.0 42.23±11.3 0.03 
Sex    0.73 
Male 27 (50.9) 79 (53.7)  
Female 26 (49.1) 68 (46.3)  
HIV related factors    
CD4 count 
(cells/uL)  
n=51 n=136 <0.001 
Very low (<200) 41(80.3) 50(36.8)  
Low (201-499) 9(17.7) 51(37.5)  
Normal (500-
2010) 
1(2.0) 35(25.7)  
Viral load 
(copies/ml) 
n=38 n=52 0.001 
LDL 0 (0.0) 12 (23.1)  
Detectable 38 (100.0) 40 (76.9)  
Concurrent morbid 
conditions 
n=53 n=103 <0.001 
TB (yes) 36 (67.9) 38(36.9)  
Other (yes) 17 (32.1) 65(63.1)  
Drug related 
factors 
   
Use of antibiotics n=51 n=143 <0.001 
Yes  41 (80.4) 46 (32.2)  
No 10 (19.6) 97 (67.8)  
Use of Anti-TB 
drugs 
n=52 n=146 <0.001 
yes 37 (71.2) 37 (25.3)  
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3.4 Types of antibiotics used by the study participants 
Overall (87 who used antibiotics and 12 who were on anti-TB but did not use 
antibiotics) 60.61% of the study participants were on common antibiotics associated 
with CDI and 24.24% did not know the type of antibiotics they used. About 12.12% of 
the study participants were not on antibiotics but were on first line anti-TB treatment, 
and 3.03% of the study participants were on antibiotics not commonly associated 
with CDI. 
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Figure 3.1: Type of antibiotics used by participants  
3.03%
60.61%
24.24%
12.12%
uncommon common
unknown No antibiotic but TB treatment
Type of Antibiotic used by the Study Participants
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3.5 The unadjusted and adjusted odds ratio (OR) of risk factors for C.difficile 
positive across selected variables 
3.5.1 Adjusting for CD4 counts 
A low CD4 count was found to be a predictor for CDI (p=0.001), after adjusting for 
the confounders, a low CD4 count was no longer a strong predictor (p=0.62) which 
was statistically insignificant. This then explains that a low CD4 count was not the 
only variable for CDI; other factors contributed to CDI. 
 
3.5.2 Adjusting for viral load 
Viral load levels were found to be a strong predictor for CDI (p<0.001); this was 
statistically significant and this was unadjusted. 
 
3.5.3 Adjusting for co-morbidities (TB) 
Having TB was a predictor for CDI; this was statistically significant (p<0.001) 
however other factors, other than TB, contributed to CDI. 
 
3.5.4 Adjusting for antibiotic use 
Using common antibiotics associated with CDI was a strong predictor for CDI 
(p<0.001). After adjusting for confounders, the use of antibiotics associated with CDI 
remained a strong predictor of outcome (CDI), thus use of common antibiotics is 
associated with risk of CDI.  
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3.5.5 Adjusting for anti-TB drugs 
The use of anti-TB drugs was a strong predictor for CDI (p<0.001). After adjusting for 
confounders, the use of anti-TB drugs remained a strong predictor of outcome.  
 
Table 3.4: Illustrates the unadjusted and adjusted odds ratio OR of CDI across 
selected variables 
 
3.5.6  Regression model for using both anti-TB drugs and common antibiotics 
The R-squared of 0.38 is the statistical measure of how close the data were fitted to 
the regression model; this explained the risk of CDI when using both anti-TB drugs 
and common antibiotics associated with CDI.  
  
Variable Unadjusted OR 
(95%CI) 
p-value Adjusted OR 
(95% CI) 
p-value 
CD4 count 
(cells/µL) 
    
Normal(Ref) –   –  –  –  
Low 6.18 (0.75-50.96) 0.09   
Very low 28.70 (3.77-
218.57) 
0.001 1.83 (0.17 – 
19.55) 
0.62 
Viral load 
(copies/ml) 
    
LDL(Ref) –   –  –  –  
Detectable 6.02 (2.98 – 12.15) <0.001 –  –  
Concurrent 
morbid 
conditions 
    
Other (Ref) –   –  –  –  
TB 3.62 (1.80-7.31) <0.001 –  –  
Use of 
antibiotics (yes) 
8.65 (3.98-18.77) <0.001 16.80 (5.41 – 
52.21) 
<0.001 
Use of Anti-TB 
drugs (yes) 
8.14 (3.77-17.56) <0.001 6.78 (2.25 – 
20.43) 
0.001 
R-squared   0.38  
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4.0 CHAPTER 4 
 
4.1 Discussion 
4.1.1 Prevalence of C.difficile infection 
Clostridium difficile is one of the important organisms causing diarrhoea and, if not 
properly treated, it  can lead to serious side effects, even death.(1) The prevalence 
of C.difficile in HIV positive patients presenting with diarrhea was found to be 53 
(26.5%) out of 200 studied patients over a 12 month period.  
 
4.2 Risk factors associated with C.difficile 
4.2.1 C.difficile and CD4 
Low CD4 count (201-499 cells µ/L) was not a strong predictor for CDI (p = 0.09) and 
unadjusted odds ratio OR (95%CI) was 6.18 (0.75-50.96), but the very low CD4 
count (<200cellsµ/L) was statistically significant (p=0.001) with unadjusted odds ratio 
OR (95%CI) of 28.70 (3.77-21.8) but  when adjusted, it was not a strong predictor for 
CDI (p= 0.62 ) as described in the results section. We can thus deduce from this 
study, that CD4 count was not the only risk factor associated with CDI.  
 
4.2.2 C.difficile and viral load 
The viral load and CD4 count are the surrogate markers for anti-retroviral treatment 
and disease progression and have been used to manage and monitor HIV infection 
for decades, thus if your HIV viral load is low you are less likely to have infection 
(opportunistic and non-opportunistic)(22).  This was the case in this study, where 
patients with high viral load had risk of CDI (p<0.001), the unadjusted odds ratio OR 
31 
 
(95%CI) was 6.02 (2.98-12.15), the Confidence interval was not broad; however the 
relation between CDI and HIV viral load has not been studied. High viral load was a 
risk factor for CDI but other factors other than viral load level contributed to CDI 
 
4.2.3 C.difficile and concurrent co-morbidities 
There were 74(37.0%) patients who were infected with TB from the cohort of 200.  
The CDI population 53 (26.5%) with TB were more than half 36 (67.9) and having TB 
was a predictor for CDI (P<0.001) with unadjusted odds ratio OR and narrow (95% 
CI) of 3.62 (1.80-7.31). These patients were already diagnosed with TB before 
presenting at CHBAH. This could be attributed to the fact that TB is one of the most 
common opportunistic infections in HIV positive patients in the world.  
A significant proportion, 82(41.0%) of the studied cohort had other co-morbidities, 
(i.e.) Community acquired pneumonia, meningitis, HIV associated malignancy, etc. 
From the CDI population, 17(32.1%) had other comorbidities. There was no direct 
correlation noted between these co-morbidities and the risk of CDI.  
 
4.2.4 C.difficile and anti-TB drugs 
The use of anti–TB drugs (all first line) was a strong predictor for CDI (p< 0.001); it 
remained a strong predictor after adjusting for confounders with adjusted OR and 
narrow therapeutic (95%CI) of 6.78 (2.25-20.43). Using anti-TB drugs was a risk 
factor for CDI. 
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4.2.5 C.difficile and antibiotics 
The common antibiotic associated with C.difficile was found to be a single risk factor 
of CDI (p<0.001) with unadjusted and adjusted odds ratio OR (95%CI) of 8.65 (3.98-
18.77) and 16.80 (5.41-52.21) respectively. 
 
4.2.6  C.difficile with both anti-TB drugs and antibiotics 
The R-squared after adjusting for confounders was 0.38, thus there was a 38% 
chance risk of having CDI if patients were using both antibiotics and anti –TB drugs. 
 
4.3 Relations and difference of findings with literature  
4.3.1 Diarrhoea and HIV 
 A study was done in North India where stool was sent for analysis of 200 HIV 
positive patients; it was found that the lower the CD4 count, the more susceptible 
patients were to diarrhoea and protozoa was the most identified organism; this is 
because of impaired immunity (23). 
 
4.3.2 C.difficile and CD4 count 
 The effect of a low CD4 count on the risk of CDI has not been well described. A 
study was done at John Hopkins with a HIV clinical cohort where they assessed the 
incidence of CDI between 01 July 2003 and– 31 December 2010. They concluded 
that incidence of CDI in HIV positive patients was twice that previously reported; they 
ascribed this to compromised immunity defined by CD4 <50 cellsµ/L (24, 25). 
This however, was not supported in our study as adjusted odds ratio showed that 
low CD4 count (<200cellsµ/L) was not the only variable associated with risk of CDI 
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(p=0.62); this was statistically insignificant. There were other risk factors associated 
with CDI. 
 
4.3.3 C. difficile and other co-morbidities 
The occurrence of CDI and HIV is established in literature (10). However the 
influence of CDI with other co-morbidities has not been well reviewed in literature. In 
South Africa, HIV is common and most of our patients, when seeking health care, 
they usually have more than one pathology, and especially TB associated conditions 
(unpublished data).  
 
4.3.4 C.difficile and anti-TB drugs 
There is minimal data on the effect of anti-TB drugs on CDI. A study in Poland 
suggested that CDI should be considered in patients who developed diarrhoea whilst 
on anti-TB medication, especially rifampicin.(26) We found that patients who were on 
anti- TB drugs were at increased risk of developing CDI an identifiable risk factor of 
CDI (p<0.001). These patients were on first line TB therapy. Some of these patients 
were using both anti-TB drugs and antibiotics which could influence the development 
of CDI (R-squared 0.38).  
 
4.3.5 C.difficile and antibiotics 
 There is substantial evidence in literature on the risk of CDI with antibiotic use. 
(17,18).  Our study findings were consistent with this , antibiotic use remained a 
strong predictor of outcome even after adjusting for confounders, with results 
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showing adjusted and unadjusted ratio and (95%CI) of 8.65 (3.98-18.77) and16.80 
(5.41 – 52.21) respectively . 
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4.3.6 C.difficile and proton pump inhibitors 
Only 8 (4%) from the 200 study participant patients were using proton pump 
inhibitors; the sample size was not enough to study its relation with CDI in our study, 
however literature has described the use of PPI as an additional risk factor to 
antibiotic use. This is however, still controversial (27, 28). 
 
4.4 Limitations of this study 
 Inadequate data (i.e). CD4 counts and viral loads were not available for all 
patients. 
  Inadequate patient histories, specifically related to antibiotic usage in the 
period prior to admission 
 Some patients were too sick to recall treatment given prior to hospitalisation. 
 Some of our patients did not know the names of antibiotics given to them prior 
to admission 
 A positive PCR is not diagnostic of CDI, it may be indicative of an 
asymptomatic carrier state or colonization without disease. 
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4.5 Conclusion 
 
 In this study, 200 HIV positive patients presenting with diarrhoea were 
evaluated for the presence of CDI and the risk factors associated with it. 
o CDI was detected in 53(26.5%). 
 The risk factors identified in our group were: 
o Anti- tuberculosis drug use (specifically Rifampicin) 
o Antibiotic use 
o Using both antibiotics and anti-Tuberculosis drugs 
o High viral load 
o Co-morbidities 
 CD4 count was not identified as a risk factor  
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6.0 APPENDICES 
6.1 Appendix 1 Copy of data collection sheet 
 
Gender:  Male Female   
Race:  Asian Black Coloured White 
Age:   Unknown  
RVD:  Positive Negative Unknown  
CD4 count:  Value Unknown  
Viral Load:  Value Unknown  
Co-morbid Disease:  Yes No  
If yes, specify:  Tuberculosis Other:  
Diagnostic Tool:  Rapid PCR If none of the above, 
which diagnostic tool was 
used? 
C-diff :  Positive Negative  
Recent antibiotic 
exposure: 
 Yes No If yes, which one and 
duration before infection? 
Use of TB drugs:  Yes No Unknown 
Use of both TB drugs 
and antibiotics: 
 Yes No Unknown 
Use of PPI:  Yes No Unknown 
If yes briefly state 
when, and duration 
before infection 
  
Clinical information and Lab Results FBC, U&E, LFT if available 
FBC  Normal Abnormal Unknown 
U+E  Normal Abnormal Unknown 
LFT  Normal Abnormal Unknown 
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6.2 Appendix 2: Copy of ethics approval 
 
